Szingapúr - angol - HSA (Health Sciences Authority)

gromark consumers enterprise pte ltd - general hospital - etg is intended to stabilize hair loss and stimulates hair regrowth in those suffering from common baldness using pulsed electrical stimulation. etg is indicated in mild to moderate cases of balding where no other pathology is present. the typical pattern in males shows an initial receding hairline and thinning on the crown of the head, with the two areas eventually joining together. in female, the pattern is a general but diffuse loss extending from the frontoparietal area throughout the crown. complete alopecia (totalis) is unlikely to be impacted by etg therapy as hair follicles are absent.

Szingapúr - angol - HSA (Health Sciences Authority)

becton dickinson holdings pte. ltd. - obstetrics & gynaecology - the breast tissue marker is intended to radiographically and sonographically mark breast tissue during a percutaneous breast biopsy procedure

Szingapúr - angol - HSA (Health Sciences Authority)

becton dickinson holdings pte. ltd. - obstetrics & gynaecology - the breast tissue marker is intended to radiographically and sonographically mark breast tissue during a percutaneous breast biopsy procedure.

Egyesült Államok - angol - NLM (National Library of Medicine)

romark laboratories, l.c. - nitazoxanide (unii: soa12p041n) (nitazoxanide - unii:soa12p041n) - nitazoxanide 500 mg - diarrhea caused by giardia lamblia or cryptosporidium parvum: alinia for oral suspension (patients 1 year of age and older) and alinia tablets (patients 12 years and older) are indicated for the treatment of diarrhea caused by giardia lamblia or cryptosporidium parvum . limitations of use alinia for oral suspension and alinia tablets have not been shown to be effective for the treatment of diarrhea caused by cryptosporidium parvum in hiv-infected or immunodeficient patients [ see clinical studies (14.2)] alinia tablets and alinia for oral suspension are contraindicated in patients with a prior hypersensitivity to nitazoxanide or any other ingredient in the formulations. risk summary there are no data with alinia in pregnant women to inform a drug-associated risk. no teratogenicity or fetotoxicity was observed in animal reproduction studies with administration of nitazoxanide to pregnant rats and rabbits during organogenesis at exposure 30 and 2 times, respectively, the exposure at the maximum recommended human dose of 500 mg twice daily based on body surface area (bsa). in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data nitazoxanide was administered orally to pregnant rats at doses of 0, 200, 800 or 3200 mg/kg/day on gestation days 6 to 15. nitazoxanide produced no evidence of systemic maternal toxicity when administer once daily via oral gavage to pregnant female rats at levels up to 3200 mg/kg/day during the period of organogenesis . in rabbits, nitazoxanide was administered at doses of 0, 25, 50, or 100 mg/kg/day on gestation days 7 to 20. oral treatment of pregnant rabbits with nitazoxanide during organogenesis resulted in minimal maternal toxicity and no external fetal anomalies. risk summary no information regarding the presence of nitazoxanide in human milk, the effects on the breastfed infant, or the effects on milk production is available. the development and health benefits of breastfeeding should be considered along with the mother’s clinical need for alinia and any potential adverse effects on the breastfed infant from alinia or from the underlying maternal condition. the safety and efficacy of alinia for oral suspension for the treatment of diarrhea caused by g. lamblia or c. parvum in pediatric patients 1 to 11 years of age has been established based on three (3) randomized, controlled studies with 104 pediatric subjects treated with alinia for oral suspension 100 mg/5 ml. furthermore, the safety and efficacy of alinia for oral suspension for the treatment of diarrhea caused by g. lamblia or c. parvum in pediatric patients 12 to 17 years of age has been established based on two (2) randomized controlled studies with 44 pediatric subjects treated with alinia for oral suspension 100 mg/5 ml. [ see clinical studies (14.1)] the safety and efficacy of alinia tablets for the treatment of diarrhea caused by g. lamblia or c. parvum in pediatric patients 12 to 17 years of age has been established based on three (3) randomized controlled studies with 47 pediatric subjects treated with alinia tablets 500 mg. a single alinia tablet contains a greater amount of nitazoxanide than is recommended for use in pediatric patients 11 years or younger. [ see dosage and administration (2.1)]. safety and efficacy of alinia for oral suspension in pediatric patients less than one year of age has not been studied. clinical studies of alinia tablets and alinia for oral suspension did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. in general, the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in elderly patients should be considered when prescribing alinia tablets and alinia for oral suspension. the pharmacokinetics of nitzoxanide in patients with compromised renal or hepatic function has not been studied. alinia tablets and alinia for oral suspension have not been studied for the treatment of diarrhea caused by g. lamblia in hiv-infected or immunodeficient patients. alinia tablets and alinia for oral suspension have not been shown to be superior to placebo for the treatment of diarrhea caused by c. parvum in hiv-infected or immunodeficient patients [ see clinical studies (14)]

Örményország - angol - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

contract pharmacal corporation - glucosamine (glucosamine sulfate), chondroitin sulfate (chondroitin sulfate sodium), ibuprofen - capsules - 250mg+ 200mg+ 100mg

Szingapúr - angol - HSA (Health Sciences Authority)

gromark consumers enterprise pte ltd - general hospital - intended for improvement of skin permeability to allow the medical practitioner / clinician to administer local ionic solutions into the body for medical purpose in a more efficient way.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - 35845 - spoon, medicine, reusable - a device used for dosing/serving medicine to a recipient. it is designed to facilitate giving different quantities and to show these in defined level markings. this device is reusable after appropriate cleansing.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - 35754 - dispenser, medication, liquid - a measuring device to dispense liquid.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - 62001 - oral/enteral syringe, reusable - this device is intended to be used for the administration of oral medication. it consists of a calibrated hollow barrel (cylinder), made of plastic and a moveable plunger. the tip is designed to mate only with enteral administration devices. it is colour-coded to distinguish it from other syringes. this is a reusable device after appropriate cleaning.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

little green pharma ltd - 37428 - connector, - a device intended to allow a syringe to connect to a bottle so that they mate creating an entity.